Yun Kim, MD
Ophthalmology · Buena Park, CANPI 1255431300
Payments from drug & device makers
Across 453 payments — averaging $24.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb Americas Inc.$5K
- Novartis$1K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$1K
- Aerie Pharmaceuticals, Inc.$1K
- Alcon$811
- Oyster Point Pharma, Inc.$469
- plus $2K from 13 others
What the payments were for
- Consulting fees$2,58823%
- Food & beverage$8,69677%
- Gifts$190%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb Americas Inc. | 74 | $4,597 |
| Novartis | 101 | $1,322 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 57 | $1,127 |
| Aerie Pharmaceuticals, Inc. | 105 | $1,124 |
| Alcon | 33 | $811 |
| Oyster Point Pharma, Inc. | 14 | $469 |
| AbbVie(2 entities) | 28 | $372 |
| Astellas Pharma US Inc | 4 | $344 |
| Amgen(2 entities) | 12 | $321 |
| Shire North American Group Inc | 8 | $175 |
| Carl Zeiss Meditec USA, Inc. | 3 | $165 |
| Kala Pharmaceuticals, Inc. | 1 | $125 |
| Sun Pharmaceutical Industries Inc. | 4 | $91 |
| Eyepoint US, Inc. | 1 | $82 |
| Eyevance Pharmaceuticals LLC | 4 | $82 |
| Tarsus Pharmaceuticals, Inc. | 1 | $35 |
| Dompe US, Inc. | 1 | $28 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Thea Pharma Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,303 in reported general payments places this provider in the 80th percentile of 2,513 ophthalmology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 2,822 | $1,939,260 |
| XiidraLifitegrast | 1,838 | $1,360,485 |
| Cyclosporine | 1,486 | $493,757 |
| ZerviateCetirizine Hcl | 392 | $170,711 |
| Alphagan PBrimonidine Tartrate | 363 | $85,367 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 289 | $62,551 |
| VyzultaLatanoprostene Bunod | 186 | $57,632 |
| TobradexTobramycin/Dexamethasone | 159 | $41,801 |
| Brimonidine Tartrate | 613 | $39,083 |
| CombiganBrimonidine Tartrate/Timolol | 143 | $37,974 |
| VascepaIcosapent Ethyl | 88 | $32,591 |
| RocklatanNetarsudil Mesylat/Latanoprost | 78 | $32,019 |
| AzoptBrinzolamide | 62 | $24,525 |
| AlrexLoteprednol Etabonate | 60 | $22,065 |
| Loteprednol Etabonate | 102 | $21,392 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Alphagan P, Combigan, Lumigan | $372 | $2,083,8253,383 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta, Zirgan | $4,597 | $1,424,5302,038 claims |
| Eyevance Pharmaceuticals LLCZerviate | $82 | $170,711392 claims |
| AlconSimbrinza, Azopt | $811 | $87,076351 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCAlrex, Loteprednol Etabonate, Besivance, Prolensa, Zylet | $1,127 | $81,650301 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $1,124 | $37,22595 claims |
| Kala Pharmaceuticals, Inc.Eysuvis | $125 | $15,33931 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $469 | $10,87417 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $91 | $7,31313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,513 ophthalmology providers in California.
Other ophthalmology in Buena Park
- Nisha AcharyaSan Francisco$33M
- David WirtaNewport Beach$18.4M
- Michael IpPasadena$10.2M
- Raymond DouglasBeverly Hills$9.7M
- Sherif El HaraziGlendale$9.2M
- Daniel SchwartzSan Francisco$8M
- Nikolas Londonla Jolla$6.1M
- Michael BerlinWest Hollywood$5.7M
- Steven JacobsonLos Angeles$4.7M
- Peter WinArcadia$4.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.